机译:PCA3和TMPRSS2-ERG基因融合的前瞻性多期评价作为前列腺癌的诊断和预后尿生物标志物
Radboud University Nijmegen Medical Centre Department of Experimental Urology Internal postal;
Noviogendix Department of Research and Development Nijmegen Netherlands;
Noviogendix Department of Research and Development Nijmegen Netherlands;
Noviogendix Department of Research and Development Nijmegen Netherlands;
Noviogendix Department of Research and Development Nijmegen Netherlands;
ZGT Hospital Department of Urology Hengelo Netherlands;
AMC University Medical Centre Department of Urology Amsterdam Netherlands;
CWZ Hospital Department of Urology Nijmegen Netherlands;
St. Elisabeth Hospital Department of Urology Tilburg Netherlands;
Scheper Hospital Department of Urology Emmen Netherlands;
Radboud University Nijmegen Medical Centre Department of Experimental Urology Internal postal;
Radboud University Nijmegen Medical Centre Department of Experimental Urology Internal postal;
Radboud University Nijmegen Medical Centre Department of Pathology Nijmegen Netherlands;
Radboud University Nijmegen Medical Centre Department of Experimental Urology Internal postal;
PCA3; Prognostic; Prostate cancer; TMPRSS2-ERG; Urinary biomarkers;
机译:PCA3和TMPRSS2-ERG基因融合作为前列腺癌诊断和预后尿液生物标志物的前瞻性多中心评估
机译:在局部晚期和转移性前列腺癌患者中开始使用曲普瑞林6个月制剂进行雄激素剥夺治疗时,评估尿液前列腺癌抗原3(PCA3)和TMPRSS2-ERG得分的变化
机译:TMPRSS2-ERG基因融合在淋巴结阳性前列腺癌中的患病率及预后意义。
机译:抗体无抗体,高敏感棱镜-SRM蛋白质组学方法在前列腺癌细胞系和肿瘤组织中监测TMPRSS2-ERG融合蛋白的应用
机译:探索泌尿表观遗传生物标志物,用于鉴定侵袭性前列腺癌
机译:PCA3和TMPRSS2-ERG基因融合体作为前列腺癌的诊断生物标志物
机译:在局部晚期和转移性前列腺癌患者中开始使用曲普瑞林6个月制剂进行雄激素剥夺治疗时,评估尿液前列腺癌抗原3(PCA3)和TMPRSS2-ERG得分的变化
机译:评估Epha2和Ephrin-a作为前列腺癌的新型诊断和预后生物标志物。